The development of a potential anti-cancer compound to optimize the standard care for patients with Colorectal cancer – the latest scientific article review by the BIOMEDICA CRO team
For the past few decades, Dr. Iwao Ojima has been working in his Stony Brook University Department of Chemistry Laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) to develop next-generation anti-cancer agents. One of these agents – a second-generation taxane conjugate in a nanoemulsion formulation (called NE-DHA-SBT-1214) – has shown great promise against solid tumors – particularly against colorectal cancer.
“A primary indication for NE-DHA-SBT-1214 is colorectal cancer, which is a very challenging cancer to deal with due to strong multidrug resistance,” says Dr. Ojima, Distinguished Professor and Director of the ICB&DD. “But it also shows promise with pancreatic cancer and prostate cancer in preclinical testing. For example, we examined NE-DHA-SBT-1214 in combination with PLD-1 antibodies for pancreatic cancer. The combination therapy exhibited superior results over the current best standard treatment against this deadly disease.”
“The funding will accelerate this new potential therapeutic into the clinic, where we hope it will provide meaningful clinical responses and potentially become a new standard of care,” mentioned Dr. Ojima.
Please find more information on the Stony Brook University website, article, “New Anti-Cancer Compound Originally Discovered at Stony Brook Takes a Major Step Towards Clinical Development”.
How does biospecimens supplier BIOMEDICA CRO support cancer research?
At BIOMEDICA CRO, we do biosample procurement through a broad network of partnered hospitals in Ukraine and supply them globally. We provide both prospective and retrospective collections of the numerous human biospecimen types and associated clinical data since 2017.
We manage our own network of 50+ direct contracts with hospitals in Ukraine in many disease areas and are always ready to make a new one if necessary. Our main area is oncology studies, so Colorectal cancer (CRC) biospecimens collection is an easy task for us.
Also, we can provide human samples from patients with other cancer types:
• Breast cancer;
• Kidney Cancer;
• Lung cancer;
• Head & Neck cancer;
• Thyroid cancer;
• Endometrial cancer, etc.
It is feasible to collect tissue samples (tumor/NAT FFPE blocks, fresh frozen tissue samples, histological slides, and lymph nodes), blood samples (plasma, serum, buffy coat, PBMC) and other biofluids from cancer subjects.
By collecting specimens by ourselves, we ensure easy, fast and faultless communication with the executors. BIOMEDICA CRO team is in constant contact with clinical sites as well as primary investigators (physicians) and is always ready to provide you with the latest collection feedback. Direct contact with physicians ensures their proper understanding of collection details and the high quality of collected biospecimens.
All human biospecimens we provide are collected under the internal company SOPs and with your particular recommendations. Our experienced study managers bring all project steps in sync with your unique needs.
If you need a reliable partner to source Colorectal cancer (CRC) biospecimens or other human biosamples for your research, BIOMEDICA CRO is here to help.
Please email us to start our collaboration at office@biomedica-cro.com / LinkedIn to learn more about our services and how we can support your project.
